azd0780

Small moleculeexperimental

Clinical trial activity

15 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
6
Phase 3
4
Phase 4
0

Earliest trial started May 18, 2022 (NCT05384262)

Timeline

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2025

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=c1ccccn1-c1ccc(N[C@H]2CC[C@H](Nc3ncc(OC(F)F)cn3)C2)nc1
Mol. weight
414.42 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07216131Phase 1Nov 10, 2025AstraZeneca, Parexel
NCT07218900Phase 2Oct 24, 2025AstraZeneca
NCT07000136Phase 3Jun 10, 2025AstraZeneca
NCT07000357Phase 3Jun 4, 2025AstraZeneca
NCT07000123Phase 3May 28, 2025AstraZeneca
NCT06742853Phase 1Dec 20, 2024AstraZeneca
NCT06834932Phase 2/Phase 3 (Phase 3)Dec 6, 2024AstraZeneca
NCT06692764Phase 2Oct 30, 2024AstraZeneca, Fortrea
NCT06671405Phase 1Sep 25, 2024AstraZeneca
NCT06576765Phase 1Aug 8, 2024AstraZeneca
NCT06592482Phase 1Aug 2, 2024AstraZeneca, Clinical Pharmacology of Miami, Nucleus Network Ltd, Orange County Research Center, Orlando Clinical Research Center
NCT06173570Phase 2Jan 31, 2024AstraZeneca
NCT05817461Phase 1Apr 19, 2023AstraZeneca, Quotient
NCT05787002Phase 1Mar 9, 2023AstraZeneca
NCT05384262Phase 1May 18, 2022AstraZeneca, Parexel
Showing 15 of 15 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstraZenecaFor profit151532022
ParexelFor profit2012022
Clinical Pharmacology of MiamiFor profit1012024
FortreaFor profit1012024
Nucleus Network LtdFor profit1012024
Orange County Research CenterAcademic/Hospital1012024
Orlando Clinical Research CenterFor profit1012024
QuotientFor profit1012023
8 organizations
Page 1 / 1